New startup ideas · Health and bio · Healthcare and bio
startup idea
Labmesh
Agents that design, order and run preclinical experiments across a global lab network.
Labmesh gives a biotech or pharma scientist an agent that takes a hypothesis, decomposes it into assays, prices and routes each assay to a contract lab on its network, tracks samples, and returns structured results with the raw instrument files.
- AI agent as a service
- Enterprise
- $10-100B market
- Network effects, winner takes most
- Global from day one
5/5
venture judge
13
similar startups, last 2 years (94 all-time)
97%
of 4 nearest real companies still alive
yes
8 matching federal grants and programs
Direction supported by government programs and grants
Scorecard
One score that balances how trendy the idea is, the demand for it and its potential for 100x, with competition measured relative to every other idea in the catalog. Recent startup trends first, government priorities second.
78
Idea Score, 0-100 · raw 47.4 x 1.64
Crowded
competition: more crowded than 79% of ideas · headwind x0.60
+4.5
government priorities, secondary (104 matching grants)
Trend
66
Is the wave forming now? 2025-26 entrants vs 2023-24, rounds since 2025, the sector's live-batch direction, the 2026 trend analyst.
- Entrants 2025-26 vs 2023-24 (similar companies)70
- Rounds announced 2025+ in the sector68
- Sector direction (live batch)100
- 2026 trend analyst25
Demand
68
Does anyone want it? YC's current RFS, companies already paid for something similar, the operator judge, founders' yes-rate in decks, readers who would run the test.
- YC asks for it (current RFS: idea / sector)30
- Someone already pays (similar companies, recent / all-time)100
- Operator judge: real pain75
100x potential
80
Can it return a fund? The venture judge (double weight), market-size and moat axes, neighbours still alive, the technologist judge.
- Venture judge100
- Market size axis67
- Moat axis100
- Neighbours still alive62
- Technologist judge50
Score = 100 x cbrt(Trend x Demand x 100x) x (1 - 0.5 x crowding) + government bonus (max 5), calibrated so the 95th-percentile idea scores 90 (order never changes). A geometric mean: a weak pillar cannot be papered over. Percentiles are among the 272 ideas in the catalog; the terms matched were design, order, preclinical, experiments, global, biotech, pharma, scientist.
The idea in full
- What
- Labmesh gives a biotech or pharma scientist an agent that takes a hypothesis, decomposes it into assays, prices and routes each assay to a contract lab on its network, tracks samples, and returns structured results with the raw instrument files. It owns no labs; it owns the protocol translation layer and the results graph. Any scientist can start with a credit card and one assay, and teams expand from there.
- Why now
- The S26 and W26 cohorts show the demand and the gap at once: Omanta is building "a research lab for one", 10x Science and AbInitio Bio are building AI layers for protein characterization and drug manufacturing, and Harbor (yc X26) is an AI-native CRO for clinical trials, leaving preclinical experiment routing across existing labs unclaimed.
- Wedge: first customer and entry point
- Seed-stage biotechs with no in-house wet lab: start with one assay class, protein expression and binding, where protocols are standard enough to route reliably across five labs.
- Path to 100x
- Global preclinical contract research is a $10-100B annual spend routed today by relationships and email. Denser lab supply means faster and cheaper turnaround, which pulls more sponsors, which pulls more labs, and every completed run adds a protocol-to-outcome pair that no competitor can buy, so the first network to reach density compounds away from the second.
- Ceiling
- Large pharma keeps routing through preferred-vendor master agreements and never lets an agent choose the lab, leaving Labmesh with only small biotechs and a market an order of magnitude smaller.
- Closest real companies, as the generator saw them
- Harbor (yc X26) is an AI-native CRO for clinical trial operations, which is regulated and asset-owning; Labmesh stays preclinical and asset-light. 10x Science and AbInitio Bio build intelligence layers for a single stage; Labmesh sits across labs and stages and keeps the outcome data.
- Main risk
- Contract labs execute the same protocol differently enough that results are not comparable, and the results graph becomes noise instead of a training set.
Five judges
Each judge scores every idea in the catalog with a named rubric; the venture judge decides whether a card is shown at all (4-5 is venture-grade).
Venture investor
5/5
Asset-light routing across a $10-100B preclinical spend, self-serve entry, and every run adds protocol-to-outcome data a rival cannot buy.
Bootstrapper
4/5
Asset-light routing across existing contract labs, credit-card start with one assay, taking a cut of spend biotechs already send by email.
Operator
4/5
Preclinical routing by relationships and email is a $10-100B spend already flowing, and one assay with a credit card fits how scientists buy.
Technologist
3/5
Protocol translation across five contract labs is real, but owning no instruments means execution variance may make the results graph unusable.
Risk
4/5
Owns no labs, unregulated preclinical work, credit-card self-serve across five interchangeable contract labs, so no single supplier or platform can end it.
trends
2/5
Marketplace routing of contract assays predates this cycle by a decade; the cohort-gap argument is absence of rivals, not a shift enabling the product.
Similar startups in the directory
Companies whose pitch matches most of the idea's terms (design, order, preclinical, experiments, global, biotech, pharma, scientist): 94 all-time, 13 from the last two years. Same matching as Idea Check.
Making hard molecules for Pharma and Biotech
AI Inference Platform for Drug Discovery
Developer of a research intelligence platform designed to accelerate biomedical discoveries. The company's platform uses machine learning and artificial intelligence to translate both closed and open-access data into recommendations for specific experiments regarding antibody extraction, enabling researchers and scientists to run successful experiments in less time without wasting resources.
The only R&D data cloud for life sciences
The robotic cloud laboratory for the life sciences.
Provider of an application programming interface designed to offer voice communication services. The company's application programming interface offers globally available cloud API that developers can interact with to build intelligent and complex communications systems, enabling customers to build sales automation systems, order inquiry lines, use CRM applications, call routing applications, phone trees, appointment reminders as well as customize voicemail applications.
Automata is a global biotech company providing robotic automation solutions to the life sciences industry.
SFOX is a cryptocurrency trading platform designed to create a global network of exchanges to facilitate real time trading of any currency.
Scalable Personalised Cancer Treatment
Satellites for Manufacturing in Space
Evolutionary intelligence for autoimmune disease
Robot lamps that do your chores.
The generator's reference companies
Real companies the model named as closest when it wrote the card, with their fate. A check mark is a company the radar could verify in its directory.
Public money in this direction
US federal grants, SBIR/STTR awards and open opportunities from the radar's public-money feed, matched to the idea's terms; the sector totals give the context.
8
grants and programs matching the idea
1127
startup-relevant grants in Healthcare and bio
$590M
awarded in the sector, tracked
130
opportunities open now in the sector
- A novel siRNA therapeutic to prevent scarring and bleb failure after trabeculectomyawardhigh relevance
NIH / NEI · SBIR phase II · $1M · posted 2025-09-15
National Science Foundation · STTR Phase I · $305K · posted 2026-08-18
- I-Corps: Translation Potential of an organ-on-chip (OoC) microfluidic platform for pharmaceutical and biotechnology preclinical testingawardhigh relevance
National Science Foundation · I-Corps · $50K · posted 2026-08-11
NIH / NIAID · STTR phase I · $300K · posted 2026-08-10
- I-Corps: Translation Potential of a Synthetic, Biodegradable, Antibacterial Hemostatic Sealant for Trauma and Surgical Applicationsawardhigh relevance
National Science Foundation · I-Corps · $50K · posted 2026-07-29
- SBIR Phase II: Fast and Low-Energy Manufacturing of High-Performance Fiber-Reinforced Compositesawardhigh relevance
National Science Foundation · SBIR Phase II · $1M · posted 2026-07-28
- A Novel Human Intestinal Organoid Platform with Peristaltic Function for Drug Discovery and Pre-Clinical Testing in GI Motility Disordersawardhigh relevance
NIH / NCATS · SBIR phase I · $350K · posted 2026-07-15
- Collaborative Research: III: Graph-based Vector Databases, from Theory to Practiceawardhigh relevance
National Science Foundation · Info Integration & Informatics · $200K · posted 2026-07-13
Market signal
What the radar sees in Healthcare and bio: new companies by cohort year, the forming YC batch, and outcomes since the February snapshot.
Healthcare and bio · 130 → 118 → 216 → 173 → 71 new companies 2022 → 2026 · 92% aliveYC S26: 14 in this cluster, 6% of the batch (was 4% in X26) (F26 is still forming: 21 listed)Since February, of 444 YC companies here: 4 acquired, 5 shut down, 37 rewrote their pitch
Design attributes
The card is one cell of a designed set: every axis below was chosen before the text was written, and the text had to realize it.
- Buyer
- Enterprise
- Business model
- AI agent as a service
- Path to 100x
- Network effects, winner takes most
- Market size
- $10-100B market
- Capital intensity
- Capital-medium (ops, field teams)
- Speed to revenue
- Revenue in 1-3 years
- Technical depth
- Deep tech: ML, hardware, bio
- Go-to-market
- Self-serve
- Moat
- Data moat
- Geography
- Global from day one
- Regulation
- Unregulated
- Vibe
- Hot space
Listed under
An idea sits in its own sector and in any sector its text clearly touches.
More ideas like this
Health and bio · Healthcare and bio
Bylaw Health
The licensed medical group behind your API call, in fifty states.
Bylaw Health holds the professional corporations, state clinician licenses, supervision agreements and payer enrollments in every US state, and exposes them as endpoints: create a clinician, attach a supervising physician, enroll a location with a payer, submit an encounter under a compliant entity.
Health and bio · Healthcare and bio
Bayworks
Licensed GMP manufacturing bays for personalized therapies, sold as bookable capacity.
Bayworks builds standardized, FDA-registered cleanroom modules inside hospital systems and partner CDMO sites, then runs a marketplace where drug sponsors book manufacturing slots by the batch instead of signing multi-year suite reservations.
Health and bio · Healthcare and bio
Assaygrid
Predicts which lab runs will fail before reagents are consumed, across every instrument vendor.
Assaygrid connects to the instrument fleet of pharma, biotech and industrial R&D organizations, learns from run telemetry, reagent lots, operator steps and outcomes, and flags runs likely to fail plus the parameter change that fixes them.
Health and bio · Healthcare and bio
Overturn
Agents that fight payer denials for health systems, then sell what wins.
Overturn deploys an agent workforce inside a health system's revenue cycle that reads each denial, pulls the governing payer medical policy, assembles the clinical record and files the appeal, working through existing EHR and clearinghouse integrations rather than new infrastructure.
Health and bio · Healthcare and bio
ChartRail
The consented medical-records rail every AI clinic runs on.
An API that lets AI-native care companies pull a patient's complete medical record with verifiable consent, by operating as a qualified participant in the national health information exchange framework and as a registered clearinghouse.
Health and bio · Healthcare and bio
Claimsmith
The agent platform where healthcare's back office gets rebuilt by everyone but us.
Claimsmith is a no-code platform where hospitals, billing companies, and health IT vendors build and run AI agents for administrative work: eligibility checks, prior authorization, claims appeals, and records chasing.
Fictional company written 2026-08-23 from MarkosWeb data; the companies, grants and numbers around it are real and tracked. Treat the idea as a research prompt, not a plan.